Genitope gets data safety monitoring board approval to continue MyVax clinical trial

By Elaine Rigoli

Tampa, Fla., March 31 - Genitope Corp. said that after reviewing safety data from the phase 3 clinical trial of the company's lead product candidate, MyVax personalized immunotherapy, the independent data safety board noted no concerns and recommended that the trial continue as planned.

The board examined data from all 287 randomized patients, who have previously untreated follicular non-Hodgkin's lymphoma.

The clinical trial is designed to evaluate the safety of MyVax and whether a statistically significant increase in progression-free survival is observed in patients receiving MyVax personalized immunotherapy as compared to patients receiving the control substance.

Genitope said it anticipates that the next planned interim analysis of data from the phase 3 clinical trial for efficacy will occur in mid 2006.

Genitope is a biotechnology company located in Redwood City, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.